News
FDA Approves Nucala for Chronic Obstructive Pulmonary Disease
By Stephanie Brown HealthDay ReporterFRIDAY, May 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD).
Medpage Today on MSN12h
FDA Approves Mepolizumab for COPDMepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...
While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...
At ATS 2025, data from the Phase III MATINEE trial reinforced the efficacy of Nucala in reducing exacerbations in COPD ...
GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence. Meanwhile, the Committee for Medicinal Products for Human Use recommended Blenrep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback